✦ LIBER ✦

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

✍ Scribed by Pujade-Lauraine, Eric (author);Hilpert, Felix (author);Weber, Béatrice (author);Reuss, Alexander (author);Poveda, Andres (author);Kristensen, Gunnar (author);Sorio, Roberto (author);Vergote, Ignace (author);Witteveen, Petronella (author);Bamias, Aristotelis (author);Pereira, Deolinda (author);Wimberger, Pauline (author);Oaknin, Ana (author);Mirza, Mansoor Raza (author);Follana, Philippe (author);Bollag, David (author);Ray-Coquard, Isabelle (author)

Book ID: 123622442
Publisher: American Society of Clinical Oncology
Year: 2014
Tongue: English
Weight: 250 KB
Volume: 32
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2013.51.4489

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab Combined With Chemotherapy f

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

✍ Pujade-Lauraine, Eric (author);Hilpert, Felix (author);Weber, Béatrice (author); 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 250 KB

Bevacizumab Combined With Chemotherapy f

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

✍ Pujade-Lauraine, Eric (author);Hilpert, Felix (author);Weber, Béatrice (author); 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 250 KB

Symptoms and adverse effects with chemot

Symptoms and adverse effects with chemotherapy±bevacizumab for platinum-resistant recurrent ovarian cancer: Analysis of the phase III AURELIA trial

✍ Hilpert, F.; Fabbro, M.; Rubio, M. Jesus; Reuss, A.; Rosenberg, P.; Panici, P. B 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

OCEANS: A Randomized, Double-Blind, Plac

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

✍ Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Hus 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 348 KB

A Phase III Randomized, Open-Label, Cont

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB

Final analysis of overall survival in OC

Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

✍ Aghajanian, C.; Goff, B.A.; Nycum, L.R.; Wang, Y.; Husain, A.; Blank, S.V. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 116 KB